News dal mondo
21
Apr
TGA clarifies therapeutic goods are unaffected by chemical production and import ban
TGA has clarified the impact of Australia’s industrial chemicals standards on medicines, medical devices, and biologicals. Responding to stakeholder queries, TGA said therapeutic goods are not affected by prohibitions imposed under the Industrial Chemicals Environmental Management Standard (IChEMS). The framework prohibits the import, manufacture, and use of specified chemicals in Australia. Certain PFAS chemicals, UV-328, and Dechlorane Plus are among the chemicals covered by IChEMS. TGA said IChEMS does not apply to chemicals used for therapeutic purposes. That limitation of the standard’s scope extends to the primary and secondary packaging of medicines and biologicals, as well as to the primary packaging, instructions for use, and spare parts of medical devices. The agency posted two statements about the exemption of medical devices from the PFAS ban last year. While TGA’s second statement clarified that medicines and biologicals are exempt from the ban, neither notice addressed chemicals other than PFAS. [RAPS]
08
Mag
Farmaceutica, Gemmato: 'per Testo unico deadline entro dicembre'
"Il Testo unico sulla legislazione farmaceutica, che ha come obiettivo quello compendiare 800 fra...
08
Mag
Min. Salute Gemmato: “Testo unico farmaceutico entro dicembre 2026”
Il sottosegretario alla Salute indica la tabella di marcia della riforma. Al centro accesso ai farmaci...
08
Mag
Precursori droghe: controllo esteso a 9 nuove sostanze dal 18 settembre 2026
Regolamento delegato (UE) 2026/314 della Commissione del 9 febbraio 2026 recante modifica del regolamento...
08
Mag
US FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
The U.S. Food and Drug Administration (FDA) on Wednesday unveiled a one-day inspectional assessment...
le ultime news
20 Mar
Iran, blocco Hormuz su produzione farmaci: 'se dura ci sarà impatto tra 6 mesi'
19 Mar
Nuove norme UE sui farmaci: più incentivi all’innovazione e controllo della disponibilità
19 Mar
As Iran war squeezes Middle East drug shipments, experts warn of longer-term effects on US manufacturing, generics
19 Mar
Farmalabor: investiti 8,5 milioni in un progetto per le malattie rare
17 Mar
EMA Management Board: highlights of March 2026 meeting
13 Mar
Dal China all’India-shoring, il rischio di una nuova dipendenza
11 Mar
EU Finalizes Pharma Reform Package, Clarifies New Rules On Modular Market Protection
11 Mar
PFAS restriction proposal: ECHA’s Socio-Economic Analysis Committee agrees its draft opinion